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Abstract
Background: Colloid fluids supplemented with adequate combinations of coagulation factor concentrates with the
capability to restore coagulation could be a desirable future treatment component in massive transfusion.
Methods: Starting from a coagulation factor and blood cell-free albumin solution we added Prothrombin Complex
Concentrate, Fibrinogen Concentrate and Factor XIII in different combinations and concentrations to analyze their
properties to restore thromboelastometry parameters without the use of plasma. Further analysis under the
presence of platelets was performed for comparability to whole blood conditions.
Results: Albumin solutions enriched with Fibrinogen Concentrate, Factor XIII and Prothrombin Complex
Concentrate at optimized concentrations show restoring coagulation potential. Prothrombin Complex Concentrate
showed sufficient thrombin formation for inducing fibrinogen polymerization. The combination of Prothrombin
Complex Concentrate and Fibrinogen Concentrate led to the formation of a stable in vitro fibrin clot. Fibrinogen
and Factor XIII showed excellent capacity to improve fibrin clot firmness expressed as Amplitude at 10 min and
Maximal Clot Firmness. Fibrinogen alone, or in combination with Factor XIII, was able to restore normal Amplitude
at 10 min and Maximal Clot Firmness values. In the presence of platelets, the thromboelastometry surrogate
parameter for thrombin generation (Clotting Time) improves and normalizes when compared to whole blood.
Conclusions: Combinations of coagulation factor concentrates suspended in albumin solutions can restore
thromboelastometry parameters in the absence of plasma. This kind of artificial colloid fluids with coagulation-
restoring characteristics might offer new treatment alternatives for massive transfusion.
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Background
Massive bleeding can cause severe intravascular hypovol-
emia with significant hypoperfusion of peripheral tissues
leading to life-threatening hemorrhagic shock. The cor-
rection of the underlying hypovolemic state with con-
ventional resuscitation fluids like crystalloid or colloid
solutions contributes to bleeding associated coagulopa-
thies by dilution of plasma coagulation factors [1]. De-
terioration of physical clot strength and, in a later stage
of prolonged bleeding, reduced thrombin generation po-
tential are the principal coagulopathic patterns found
when monitored by viscoelastic testing [2]. Viscoelastic
testing, like rotational thromboelastometry (TEM), is fre-
quently used as a point-of-care tool in severe bleeding,
providing comprehensive information about the visco-
elastic and temporal characteristics of blood clot forma-
tion [3]. Thereby identified coagulopathies caused by
single- or combined coagulation factor deficits are in-
creasingly treated with coagulation factor concentrates
(CFC), like Fibrinogen Concentrate (FC), Prothrombin
Complex Concentrate (PCC) and Factor XIII Concen-
trate (FXIIIC) [4–6]. The principle goal of CFC-based
treatment strategies is to reduce transfusion rates of
allogeneic blood products and adverse events associated
with plasma transfusion [7]. There is growing scientific
evidence that coagulation factor deficiencies in bleeding
patients can be effectively and safely treated with CFCs
with some studies showing better outcomes for CFCs
when compared to plasma transfusion [8–10]. By con-
trast there is a certain paucity of high-quality evidence
in favor of plasma, although plasma transfusion is still a
widely accepted standard of trauma and non-trauma
massive transfusion protocols [11]. The high acceptance
of plasma transfusion among many physicians might be
explained, not only by its stabilizing effect on the coagu-
lation system providing a close-to-physiological factor
composition but also by its resuscitation fluid quality
with good intravascular volume effects in patients with
hemorrhagic shock. Currently, no alternative products
are available which share these two characteristics with
human plasma. Therefore, colloid fluids providing
adequate intravascular volume effects combined with
maintained hemostatic properties could be an interesting
future treatment component in massive transfusion and
damage control resuscitation, helping to reduce plasma
transfusion and its associated side effects under
maintenance of the stabilizing effects on coagulation and
hemodynamics.
We hypothesized, that an optimized and well-balanced
combination of different coagulation factors, reconstituted
in an albumin-based carrier solution, would provide basic
clotting characteristics with TEM responses compatible
with whole blood if tested under the presence of platelets.
In this study, we used a thromboelastometric approach
to analyze modifications of viscoelastic parameters in a
plasma-, and blood cell-free environment. It is technic-
ally feasible to perform thromboelastometric analysis in
such conditions, although this approach has been limited
to its use in laboratory investigations [12, 13].
Methods
Experimental design
This study (protocol number IIBSP-CFC-2013-165) was de-
signed to explore in vitro the capability of CFCs to restore
coagulation properties. A series of experimental studies
were performed to define the optimal factor concentrations
of such coagulation resuscitating fluid (CRF). Starting from
a coagulation factor and blood cell-free solution of 5% hu-
man albumin we added PCC, FC and FXIIIC in different
combinations and concentrations to analyze their proper-
ties to restore thromboelastometric parameters without the
use of plasma. The optimal CFC composition was further
analyzed under the presence of platelets to improve com-
parability to whole blood conditions.
All coagulation factors – fibrinogen (FGN), factor XIII
(FXIII) and prothrombin complex (PC) factors II, VII, IX
and X - were derived from commercial CFCs (FC, FXIIIC
and PCC). The optimal concentration of FGN and FXIII
in CRF was determined by direct comparison to clot firm-
ness parameters of plasma from an internal control group.
The optimal concentration of PC coagulation factors was
determined by the shortest obtained clotting time (CT)
value. CRF was considered as having a coagulation restor-
ing potential to allow consideration as plasma substitute,
if thromboelastometric responses of the final CRF com-
position lay within the normal range for whole blood
when tested in presence of platelets [14].
Plasma reference values for thromboelastometry
parameters
TEM parameters were determined from plasma from
healthy volunteers to define the reference range for
Koller et al. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine           (2021) 29:57 Page 2 of 11
clotting time (CT), the amplitude at 10 min (A10) and
maximum clot firmness (MCF) under blood cell-free
conditions. For this purpose, we collected blood sam-
ples from 33 healthy volunteers who had not taken
medication affecting coagulation- or platelet-function
in the last 10 days. A sample of 4.5 ml of blood was
drawn from each donor in citrated tubes (0.129 M)
and centrifuged at 3200 rpm for 25 min. Plasma
supernatant was used for FIBTEM analysis. FIBTEM
was used to minimize viscoelastic signals associated
with residual platelets after centrifugation. The 95%
confidence interval of the obtained values was defined
as the reference range for plasma. The established
reference ranges were later used for comparison with
TEM responses of CRF samples to determine the
optimized CRF factor concentration.
Study samples
Composition of study samples
Study samples were composed of an artificial fluid solu-
tion (AFS) based on 5% human albumin together with
different CFC combinations and concentrations. 20% hu-
man Albumin (Grifols®, Spain) was diluted with an iso-
tonic, balanced, crystalloid solution (Viaflo Plasmalyte®
148, Baxter, Spain) to a final albumin concentration of
5% correspondent to high physiologic plasma concentra-
tions for albumin. Calcium gluconate was added to
achieve a physiological free ionized calcium concentra-
tion of 1.0–1.2 mmol/l. The solution was buffered with
TRIS buffer (1M) to a physiological pH range between
7.36–7.45. Electrolyte concentrations and pH were mea-
sured on the blood gas analyzer Radiometer®ABL 90 Flex
to confirm the physiological composition of our stem
solution.
All factor concentrates were provided by CSL Behring.
The different coagulation factor concentrates (CFC)
were reconstituted in stock solutions. PCC (Beriplex,
CSL Behring GmbH, Germany), FC (Riastap, CSL Beh-
ring GmbH, Germany) and FXIIIC (Fibrogammin/Clu-
vot, CSL Behring GmbH, Germany) were used as CFCs
for this in vitro analysis. The lyophilized proteins were
reconstituted with the minimum amount of the accom-
panied provider’s solution necessary for protein dissolv-
ing, resulting in final concentrations of 0.025 IU/μl for
factor IX (FIX) as reference protein in PCC, 0.1 mg/μl
for FGN, and 0.05 IU/μl for FXIII. High final protein
concentrations in the stock solutions were necessary to
avoid dilutional effects during the preparation of the
final study samples. The stock solution was directly used
or stored at − 70 °C for later use. The final composition
of AFS free of proteins and blood cells was tested as a
negative control with EXTEM and FIBTEM subtests as
described in the thromboelastometry section.
Preparation of study samples
Aliquots of the stock solution containing coagulation
factors were added to the AFS within citrated tubes to
reach the defined final factor concentration. The study
samples were warmed to 37 °C in the provided warming
chamber of the ROTEM® machine before testing.
Variable CFC concentrations and platelet count
The effect of various combinations of CFC-derived co-
agulation factors suspended in AFS on their functional
contribution to clot formation was evaluated by TEM.
The study samples were distributed in different test
series. Within the same test series the protein concentra-
tion of only one component (FGN, FXIII or PC), or
platelet count, was gradually modified while the concen-
tration of the other components was left unchanged.
The protein concentration of PC used in our in vitro-ex-
periments is provided as IU/ml referring to the under-
lying factor IX activity, being the PC reference protein.
Three main series of tests were performed combining
different CFC-derived proteins added to the AFS:
a) Increasing PC concentrations (0.05, 0.1, 0.25, 0.5, 1,
2 and 4 IU/ml) over a fixed FGN concentration of 4 g/l;
b) Increasing FGN concentrations (0.5, 1, 2, 4, 8 and 12
g/l) over a fixed PC concentration of 1 IU/ml; c) Increas-
ing FXIII concentrations (0.1, 0.5, 1, 2, 4 and 8 IU/ml)
over a fixed PC concentration of 1 IU/ml and a fixed
FGN concentration of 4 g/l. Each concentration step of
the changing factor component defined one study
sample that was tested by TEM. The study samples were
analyzed for viscoelastic properties with the FIBTEM-S
subtest. A TEM response within the defined reference
values (Table 1) for A10 and MCF derived from internal
controls determined the optimal FGN and FXIII com-
position of the CRF. Combined FGN/FXIII preparations
with TEM responses within the normal range for A10/
MCF were given priority to single factor preparations
(FGN alone) for defining the final CRF composition.
The shortest CT value obtained in a series with increas-
ing PC concentrations defined the final PC concentra-
tion of CRF.
In a fourth test series the effect of platelets on samples
containing the final CRF composition of PC (1 IU/ml),
FGN (4 g/l) and FXIII (1 IU/ml) was evaluated adding an
increasing number of washed platelets (12.5, 25, 50, 100,
200 and 400 platelets 103/μl) obtained from healthy,
non-medicated donors. The samples were analyzed with
the FIBTEM-S and EXTEM-S subtests.
Preparation of platelet suspensions
Blood was collected into citrate/phosphate/dextrose
(final concentration of citrate of 19 mM) and centrifuged
(120 x g for 15 min) to obtain platelet-rich plasma.
Washed platelets were obtained by mixing PRP with
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equal volumes of citrate/acid citric/dextrose (93 mM so-
dium citrate, 7 mM acid citric, and 140 mM dextrose),
pH 6.5 containing 5 mM adenosine and 3mM theophyl-
line (CCD–AT) [17]. The final pellet was resuspended in
a Hanks’ balanced salt solution (136.8 mM NaCl, 5.3
mM KCl, 0.6 mM Na2HPO4, 0.4 mM KH2PO4, 0.2 mM
NaH2PO4-2H2O) supplemented with dextrose (2.7 mM)
and NaHCO3 (4.1 mM), pH 7.2, and maintained for 50
min at 37 °C before experiments were performed. Con-
centrated washed platelets were added to the study
samples to reach the established platelet counts.
Thromboelastometry
TEM analysis was performed on the ROTEM® delta ma-
chine (Rotation Thromboelastometry, TEM Inter-
national, Munich, Germany). Plastic cups were filled
with 300 μl of pre-warmed (37 °C) solutions. FIBTEM-S/
EXTEM-S subtests were used providing extrinsic coagu-
lation activation with/without cytochalasin-based deacti-
vation of platelets. FIBTEM is essentially dependent on
the FGN function. This test inhibits the platelet contri-
bution to clot formation, leaving only the clotting pro-
teins. Thus, one can observe the contribution of
functional FGN to clot formation. A minimum of three
independent measurements on different, freshly pre-
pared samples were performed for each concentration
step. Thromboelastometry measurements were per-
formed immediately after combining the different pro-
tein and/or cellular components of the study samples.
Standard TEM parameters were obtained for statistical
analysis: CT, A 10, and MCF.
Statistical analysis
The 95% confidential interval defined the normal range
for the obtained TEM parameters of the internal control
group: CT, A10, and MCF. Statistical analysis was per-
formed on SAS® 9.3 Statistical Software. The correlation
analysis of the collected data was performed on basis of
a dispersion graph for illustrating values of TEM param-
eters in function of the corresponding dose. Linear cor-
relation was analyzed on basis of the underlying
dispersion graph. In the case of linear correlation the
Pearson coefficient for linear correlation was applied.
For interpreting our data p < 0.050.05 were considered
significant.
Results
Negative control of coagulation factor free AFS samples
No response was detected in FIBTEM or EXTEM sub-
tests when performed on AFS that were not enriched
with coagulation factors. The tests resulted in an infinite
CT value and no clot formation could be detected.
Normal range of plasma tested by TEM
The 95% confidence interval of the TEM parameters de-
termined in 33 plasma samples of healthy volunteers
was defined as the “normal range” for plasma. The re-
sults are summarized in Table 1 as “Internal Control”.
The upper limit of normal for CT in our internal control
group was 53 s for EXTEM subtests and 54 s for FIB-
TEM subtests. The obtained plasma reference range for
A 10 and MCF was 17–24 mm and 18–26mm, respect-
ively. Previously published reference ranges for standard
TEM parameters for plasma and whole blood and usu-
ally accepted treatment thresholds are shortly summa-
rized in Table 1 for comparison [13–16].
Combination of PC and FGN leads to fibrin clot formation
in a plasma and platelet free environment
The combination of PC and FGN in an artificial colloid
solution free from other blood components leads to the
formation of a thromboelastometrically measurable fi-
brin clot. The formed fibrin clots were stable as no sig-
nificant deterioration of its viscoelastic integrity was
observed during the 60min TEM response. Figure 1
shows a typical TEM graph using a FGN concentration
of 4 g/l and PC at 1 IU/ml (using the concentration of
FIX as a reference). The viscoelastic properties of the
tested fluids at this coagulation factor combination (CT
117 ± 20 s, A10 10.7 ± 0.6 mm, MCF 12 ± 1.7 mm) were
located outside the aspired, predefined normal values
(Table 1), especially CT was considerably prolonged.
Table 1 Reference ranges for standard TEM parameters CT, A10, MCF. Reference ranges are presented for plasma and whole blood.
Plasma ranges are derived from an internal control group. Values from an external control group from previous studies are also
highlighted for comparison. Whole blood reference ranges are shown for comparison with TEM results of CRF under presence of
platelets. The recommended treatment thresholds are presented to provide a clinical context of the obtained TEM results
Reference ranges Plasma (Internal control)a Plasma (External control)b Whole bloodc Treatment thresholdd
CT (sec) 47–54 53–71 42–74 > 80
A10 (mm) 17–24 n.a. 43–65 < 7
MCF (mm) 18–26 17–35 49–71 < 14
a Values derived from fresh plasma from 33 healthy, non-medicated volunteers. Reference range corresponds to 95% confidence interval
b Values derived from fresh plasma as published by Schörgenhofer et al. [13]
c Values derived from whole blood as published by Lang et al. [14]
d Treatment thresholds for whole blood EXTEM-CT and whole blood FIBTEM-A10/MCF as published by
Schöchl and Schlimp [15]. and Ranucci et al. [16]
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Fibrin formation was dependent on the presence of PC
as negative controls without PC proteins ruled out spon-
taneous fibrin formation during TEM analysis.
Increasing concentrations of PC caused progressive
improvements in TEM parameters at a fixed FGN
concentration of 4 g/l
As described in Table 2, a progressive shortening of CT
was observed with increasing concentrations of PC. An
inverse association between PC concentration and CT
was observed within the 0.05–1 IU/ml concentration
range with the shortest CT detected at a concentration
of 1 IU/ml and an average CT of 117 s. This value was
significantly prolonged when compared to the CT refer-
ence range of our internal control group, to external
controls, and published treatment thresholds (Table 1).
Higher PC concentrations (> 1 IU/ml) did not further
shorten CT values. Even in very high concentrations like
4 IU/ml, CT did not further improve.
Effects of increasing concentrations of PC on fibrin
clot strength measured by A 10 and MCF were less
evident than those observed on CT. As shown in Table
2, a positive linear correlation between rising PC con-
centrations and thromboelastometry clot strength pa-
rameters was seen (Pearson correlation coefficient of
rho = 0.65, 0.57 and p-values < 0.0013, 0.0063 for A10
and MCF respectively).
According to these data, a concentration of 1 IU/ml
PC for the final CRF composition was determined.
Rising FGN concentrations improved clot strength related
parameters at a fixed PC concentration of 1 IU/ml
Based on the previous results, a fixed PC concentration
of 1 IU/ml was chosen for this test series as it provided
the shortest CT values in our model. As summarized in
Table 3, a negative non-linear correlation was seen be-
tween increasing FGN concentrations and measured CT
values. This effect was more pronounced in the lower
FGN range between 0.5 and 2.0 g/l and became less sig-
nificant with higher FGN concentrations above 2 g/l.
Moreover, FGN concentrations rising from 0.5 to 12 g/
l improved the TEM parameters that characterize the
clot strength with a strong positive correlation between
FGN concentrations and the corresponding TEM pa-
rameters (Pearson correlation coefficient of rho = 0.98
and p-values of < 0.0001 for both A10 and MCF respect-
ively, Table 3). At a physiological FGN concentration of
4 g/l the measured TEM responses (11/12 mm for A 10/
MCF) were slightly below the desired TEM range of 17
mm. The final FGN concentration for CRF composition
of 4 g/l was determined in synopsis with the results
achieved in combination with FXIII.
Increasing concentrations of FXIII (0.1, 0.5, 1, 2, 4, 8 IU/ml)
enhanced clot strength at fixed concentrations of PC (1
IU/ml) and FGN (4 g/l)
Fixed concentrations of FGN (4 g/l) and PC (1 IU/ml)
were used in this experimental setting. FXIII effects on
fibrin clot strength were evaluated by A 10 and MCF. As
shown in Table 4, a moderate to high positive
Fig. 1 Combination of PCC and FGN leads to fibrin clot formation in
a plasma and platelet free environment. Figure is representative for
fibrin clot formation under a combination of PCC at 1 IU/ml with
FGN at 4 g/l.
Table 2 Analysis of viscoelastic parameters in albumin-based colloid solutions enriched with prothrombin complex concentrate
(PCC) and fibrinogen (FGN). Different PCC concentrations (0.05, 0.1, 0.25, 0.5, 1, 2, 4 IU/ml) were combined with fixed fibrinogen
(FGN) concentrations of 4 g/l. The albumin concentration was maintained stable at 5%. Negative controls on PCC-free solutions did
not show any measurable ROTEM response (infinite CT). A minimum of three repeats for each concentration step was performed.
The value in bold letters is prolonged (>80s) but still reflects the optimal PCC response for CRF composition
Increasing PCC concentrations over FGN 4 g/l
PCC conc.a 0,05 0,1 0,25 0,5 1 2 4
CTb,* 613 ± 251 337 ± 46 216 ± 50 168 ± 22 117 ± 20 95 ± 40 115 ± 18
A10c,** 5.7 ± 1.5 6.3 ± 1.5 6.7 ± 0.6 8.3 ± 1.5 10.7 ± 0.6 14 ± 4.3 11.7 ± 2.1
MCFc,*** 6.3 ± 1.5 7.3 ± 2.1 7 ± 1 9.3 ± 2.3 12 ± 1.7 14.3 ± 4.9 12 ± 2.6
*p < 0,0001, Pearson rho 0,9 for1/CT, **p = 0,0013, Pearson rho 0,65, ***p = 0,0063, Pearson rho 0,57
aPCC concentrations in IU/ml refer to final factor IX concentrations as reference protein in this product
bCT in seconds. Mean values ± SD
cA10 and MCF in mm. Mean values ± SD
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correlation was observed for the Pearson correlation coef-
ficient between rising FXIII concentrations and A10 and
MCF (p-values of 0.004 and 0.002, respectively). The pre-
viously observed TEM response at a FGN concentration
of 4 g/l (MCF 12mm) in a FXIII-free environment (MCF
12mm), significantly improved to MCF of 24mm by add-
ing 1 IU/ml of FXIII, thus reaching the upper limit of our
predefined range for normality. No additional effect or
statistical correlations were observed for other tested
TEM parameters (CT). According to the combined data
on FGN and FXIII, final concentrations of 4 g/l for FGN
and 1 IU/ml for FXIII were determined for further analysis
of CRF under the presence of platelets.
Platelets completely restore whole blood TEM
parameters, including CT
The impact of increasing platelet counts (12.5, 25, 50,
100, 200, 400 × 103/μl) on various TEM parameters was
investigated under the previously established conditions
using fixed CRF concentrations of PC (1 IU/ml), FXIII
(1 IU/ml) and FGN (4 g/l) as this combination provided
optimal values for CT and clot strength in TEM studies.
The presence of platelets (in the optimally designed
CRF) significantly improved fibrin clot strength parame-
ters assessed by A10 and MCF (Fig. 2a and b). A moder-
ate to high positive correlation was observed between
rising platelet concentrations and A10 and MCF mea-
surements (Pearson correlation coefficient of rho = 0.89/
0.86, respectively and p-values of 0.0001). Clot strength
values reached the normal range for EXTEM whole
blood under a minimum platelet concentration around
100 × 103/μl, as calculated from a regression analysis. No
effect on clot strength was observed for platelets in the
FIBTEM tests performed in parallel.
As shown in Fig. 2c, the presence of platelets (in the
optimal CRF) shortened CT. A moderate to high nega-
tive correlation was observed with rising platelet concen-
trations and measured CT (Pearson correlation
coefficient of rho = − 0.80, p < 0.0001). TEM values
reached normal whole blood CT values for EXTEM sub-
tests under a minimum platelet concentration of around
100 × 103/μl.
As shown in Table 5, CRF at PC 1 IU/ml, FGN 4 g/l,
FXIII 1 IU/ml reached TEM parameters comparable to
whole blood EXTEM reference ranges when tested
under the presence of 100 × 103/μl platelets.
Discussion
Data from our in vitro study demonstrate that it is pos-
sible to restore coagulation properties by combining de-
fined concentrations of coagulation factor concentrates
in an albumin-based colloid solution. The viscoelastic
clot formation parameters A 10 and MCF observed in
CRF were comparable not only to human plasma, but
also to whole blood under the presence of platelets. The
surrogate parameter for thrombin generation, CT, was
prolonged when compared to our internal control group,
Table 3 Analysis of viscoelastic parameters in albumin-based
colloid solutions enriched with fibrinogen (FGN) and
prothrombin complex concentrate (PCC). Different FGN
concentrations (0.5, 1, 2, 4, 8, 12 g/l) were combined with fixed
PCC concentrations of 1 IU/ml. The albumin concentration was
maintained stable at 5%. Negative controls on fibrinogen free
solutions did not show any measurable ROTEM response
(infinite CT). A minimum of three repeats for each concentration
step was performed. The values in bold letters reflect the
optimal FGN response for CRF composition
Increasing FGN concentrations over PCC 1 IU/ml
FGN
conc. a
0,5 1 2 4 8 12
CT b,* 4032 ±
1949
620 ± 620 221 ± 90 117 ± 20 154 ± 27 198 ± 1
A10c,** n.a. 2.7 ± 0.6 3.6 ± 0.6 10.7 ± 0.6 25.7 ± 4.2 47 ± 1.4
MCFc,*** n.a. 3.7 ± 0.6 3.3 ± 0.6 12 ± 1.7 26.3 ± 3.1 49.5 ± 3.5
*p < 0,0001, Pearson rho 0,84 for1/FGN, **p < 0,0001, Pearson rho 0,98, ***p <
0,0001, Pearson rho 0,98
aFGN concentrations in g/l
bCT in seconds. Mean values ± SD
cA10 and MCF in mm. Mean values ± SD
Table 4 Analysis of viscoelastic parameters in albumin-based colloid solutions enriched with factor XIII (FXIII), prothrombin complex
concentrate (PCC) and fibrinogen (FGN). Different FXIII concentrations (0.1, 0.5, 1, 2, 4, 8 IU/ml) were combined with fixed PCC and
FGN concentrations of 1 IU/ml and 4 g/l, respectively. The albumin concentration was maintained stable at 5%. Negative controls for
FXIII- free solutions are represented by the corresponding compositions shown in Tables 2 and 3. A minimum of three repeats for
each concentration step was performed. The values in bold letters reflect the optimal FXIII response for CRF composition
Increasing FXIII concentrations over PCC 1 IU/ml and FGN 4 g/l
FXIII conc. a 0.1 0.5 1 2 4 8
CTb,* 123 ± 12.7 128 ± 17.3 135.3 ± 12.7 122.3 ± 7.5 133.5 ± 29 133.3 ± 22.2
A10c,** 12.5 ± 0.7 16.3 ± 1.5 21.3 ± 2.1 24.3 ± 2.3 30.3 ± 11.4 30.7 ± 9.9
MCFc,*** 13.5 ± 0.7 18.7 ± 2.1 23.7 ± 3.1 26.7 ± 4.6 32.3 ± 10.4 35.7 ± 12.4
*no correlation, **p = 0,004, Pearson rho 0,65, ***p = 0,002, Pearson rho 0,69
aFXIII concentrations in IU/ml
bCT in seconds. Mean values ± SD
cA10 and MCF in mm. Mean values ± SD
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but reached normal levels for whole blood when ana-
lyzed in presence of platelets at 100 × 103/μl [14]. Fluid
substitutes like CRF could be an interesting treatment
option, with clinical indications comparable to those of
fresh frozen plasma.
Massive bleeding, independent of its etiology (trauma,
obstetrical or surgical), usually includes high ratio FFP
transfusion guided by institutional massive transfusion
protocols, based on a large body of evidence favoring
plasma against coagulation factor-free resuscitation
fluids [11, 18]. This hemostatic resuscitation concept,
however, is insufficient to avoid massive transfusion-
associated multifactor coagulopathies [19]. Factor con-
taining fluids for volume therapy, like CRF, that are
characterized by optimized viscoelastic properties could
be an appealing new treatment component. Additional
point-of-care monitoring would still allow for goal-
directed top-up corrections, but monitoring intensity
could be reduced. Easy storage of the CRF components
at 4 °C, immediate availability without thawing time, and
the universal applicability, independent of blood group
compatibility, could provide both logistic and clinical ad-
vantages of this new product compared to frozen
plasma. The clinical indications for CRF administration
could largely be analog to those of plasma, focusing on
uncontrolled bleeding events related to multifactor defi-
ciencies in hypovolemic patients, in which ongoing
factor-free fluid therapy could cause further deterior-
ation of the basic coagulation mechanisms. In these ur-
gent scenarios CRF could provide shorter decision-to-
treatment times than those known for plasma transfu-
sion. CRFs could easily be held available, independent of
blood bank facilities, in all areas exposed to massive
bleeding scenarios, like operating theatres, ICUs, delivery
rooms, emergency departments and even in prehospital
emergency- or military settings.
Future clinical studies in massive transfusion scenarios
will have to show if substituting plasma by CRF is feas-
ible and if equal efficacy in terms of hemodynamic and
Fig. 2 Analysis of viscoelastic parameters of CRF, defined as albumin-based colloid solution containing PCC [1 IU/ml], FXIII [1 IU/ml] and FGN
[4 g/l]). Different platelet concentrations (12.5, 25, 50, 100, 200, 400 × 103/μl) were combined with CRF. A minimum of three repeats for each
concentration step was performed. The continuous line in the graph shows the lower limit of normal range for whole blood TEM parameters. a
Effect of different platelet concentrations on A10. b Effect of different platelet concentrations on MCF. c Effect of different platelet concentrations
on CT
Table 5 Comparison of whole blood reference ranges with TEM
results for CRF under presence of 100 × 103/μl platelets
WHOLE BLOODa CRF + PLATELETS
CT (s) 42–74 74 +/− 5
A 10 (mm) 43–65 45 +/− 3
MCF (mm) 49–71 59 +/− 2
a Whole blood reference ranges as published by Lang et al. [14]
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coagulation stability will be provided. Furthermore clin-
ical trials will have to show if plasma-specific adverse
events like “transfusion-related acute lung injury (TRAL
I)” or “transfusion-related immune modulation (TRIM)”
would be less frequent under treatment of purified
plasma-derived components like CFCs or albumin. It is
not finally established from previous clinical studies, if
the overall complication rate, especially when compared
to solvent and detergent treated pooled plasma (S/D
plasma), really results in a better safety profile for factor
concentrates. Next to these still to be answered clinical
issues, current prices for the final CRF components
would imply a major economic obstacle for the imple-
mentation of this product into clinical routine, even if
outcome superiority compared to plasma-based standard
of care could be demonstrated in future clinical studies.
Human albumin 5% was chosen as carrier solution for
the coagulation factor compound of our CRF for differ-
ent reasons. First, colloids were favored against crystal-
loids, because accurately defined coagulation factor
concentrations within a predefined volume of a resusci-
tation fluid would only make sense, if the underlying
carrier showed adequate and sustained volume effects in
the intravascular space. Second, the colloid should not
interfere in a significant manner with the coagulation
system. Although all colloid solutions show dilutional ef-
fects, albumin solutions, together with gelatins, seem to
cause less colloid-specific, detrimental effects on platelet
function or fibrin polymerization than other colloids,
like dextrans, or starches [20, 21]. We preferred albumin
against gelatins to optimize comparability to FFP in fu-
ture trials. Experimental studies show that albumin-
based colloid solutions provide stabilizing effects on the
endothelial barrier and show intravascular plasma ex-
pander effects of nearly 100% [22, 23]. By contrast, no
such effects on the endothelial barrier could be demon-
strated for CFCs [24]. The administration of well-
balanced coagulation factors in carrier solutions with
constant intravascular volume effects might be a safe
way to treat bleeding associated coagulopathies, as “over-
shot” peak plasma concentrations caused by the infusion
of highly concentrated factor formulas (as under non-
diluted CFC administration) would be avoided. The
intravascular volume effect of colloidal resuscitation
fluids seems to be context-sensitive and correlated to
the integrity of the endothelial glycocalyx layer. There is
growing evidence that in special clinical conditions like
sepsis and trauma, characterized by elevated glycocalyx
shedding rates, the volume expander rate of isooncotic
colloids would be less than predicted. The underlying
glycocalyx disruption seems to be partially driven by a
“low-protein environment” caused by aggressive crystal-
loid or synthetical colloid fluid treatment. By contrast,
protein containing resuscitation fluids like plasma or
albumin-based colloids seem to provide protective ef-
fects against glycocalyx shedding. This albumin-
mediated protection of the glycocalyx layer is currently
demonstrated in mostly preclinical, in-vitro studies, and
it remains a matter to future studies if this translates
into a clinically detectable advantage of albumin contain-
ing resuscitation fluids [25, 26] .
Hemostasis is a result of coordinated interactions be-
tween platelets and coagulation mechanisms [27]. Co-
agulation mechanisms necessary for consolidation of
platelet mediated primary hemostasis require a cascade
of enzymatic reactions leading to the formation of fibrin
[15, 28, 29]. Results of the present study indicate that co-
agulation mechanisms can be reproduced using a re-
stricted number of coagulation factors suspended in a
neutral fluid. To our knowledge, this is the first experi-
mental study that has been able to demonstrate that the
combination of commercially available CFCs in an initial
coagulation factor- and blood-cell-free solution leads to
the formation of a stable in vitro fibrin clot. The initi-
ation of the coagulation in this fluid requires the use of
EXTEM or FIBTEM reagents whose components (cal-
cium, phospholipids and tissue factor) would trigger the
activation of the prothrombin complex coagulation fac-
tors VII, IX, X and II contained in commercial PCCs [6].
These coagulation factors lead to sufficient thrombin
generation and warrant the basic activating mechanism
of the coagulation system to sustain in vitro fibrin
polymerization. FGN provides the structural clotting
substrate supporting secondary hemostasis [30]. The ne-
cessary FGN concentration in CRF to reach normal
TEM values (when combined with FXIII) was found in
the range of physiological plasma concentrations, around
4 g/l for FGN and 0,5–1 IU/ml for FXIII. FXIII cross-
links fibrin, completing blood coagulation and protecting
the hemostatic plug from the fibrinolytic activity at the
clot formation site. In vitro studies demonstrated that
supplementation with FXIIIC increases clot firmness
assessed by TEM in perioperative patients with elevated
FGN and reduced FXIII levels [31]. However, in another
in vitro model of massive transfusion in trauma, com-
bination therapies with FC and fresh frozen plasma, but
not FXIIIC, improved both coagulation kinetics and
fibrin-based clot strength [32, 33]. Our present study in-
dicates that increasing concentrations of FXIII enhance
clot strength at fixed concentrations of PC (1 IU/ml) and
FGN (4 g/l). Consistently, there is further evidence that
FXIII deficiency will impair FGN function and fibrin for-
mation, suggesting an inverse link between low FXIII
levels and enhanced thrombin generation, modifying the
structure-function relationship of fibrin to support
hemostasis [34]. Data derived from clinical studies
propose maintenance of 50–60% of FXIII activity to
avoid bleeding tendency in the perioperative setting [35].
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CRF compositions without FXIII, yielding comparable
clot strength in TEM when compared to our final com-
position, are possible from a theoretical point of view.
We decided to add a purified source of FXIII to our final
CRF composition despite the high potential of
concentrate-derived FGN on viscoelastic clot strength to
maintain a close-to-physiological factor composition.
The safe upper limit of FC treatment has not been
precisely defined. It is currently suggested that plasma
levels of FGN should reach 1.5 to 2 g/l in bleeding pa-
tients [36]. There is a clear tendency, as reported in dif-
ferent guidelines, to recommend elevating plasma FGN
in some clinical situations [8, 37, 38]. Taking into con-
sideration the results of our TEM studies it may be diffi-
cult to maintain a well-balanced coagulation factor
composition during a long-lasting, high-dynamic bleed-
ing event if supplements are only point-of-care driven
and punctual. In this context, a fixed ratio of clotting
factors in CRFs administered under volume therapy
could provide more balanced stability within the com-
plex multifactor system of blood coagulation than single
factor substitutes as proposed in current algorithms.
CT in TEM is partially dependent on thrombin gener-
ation. Direct anticoagulants reducing thrombin gener-
ation definitively prolong CT [39]. Platelets contribute to
enhance thrombin generation, accelerate CT, and in-
crease MCF. Additionally, platelet phospholipids dra-
matically contribute to the amplification of coagulation
mechanisms, thus potentiating thrombin generation and
fibrin polymerization. Fibrin then interacts with acti-
vated platelets and plays a critical role in MCF. CT
values of platelet-free CRF samples in our in-vitro exper-
iments were significantly prolonged when compared to
plasma CT levels of our internal control group. Several
reasons may account for these findings:
First, our in vitro samples were completely free of any
phospholipids or cell membrane fragments that could
influence factor activation. Consequently, the addition of
platelets to CRF containing 1 IU/ml PC, 4 g/l of FGN
and 1 IU/ml FXIII leads to the normalization of CT and
MCF. It could be assumed from our studies that, when
combined with CRF, a platelet count around 100 × 103/
μl should be required to fully reconstitute TEM parame-
ters to levels observed in whole blood studies (see Fig.
2a-c). CT values above 80 s are considered to reflect
pathological thrombin generation and are generally ac-
cepted as treatment threshold. CT values of CRF com-
bined with platelets were significantly shorter than this
generally recommended treatment thresholds [15]
(Tables 1 and 5).
Second, the used PCC in our experiments contains
heparin. Other study groups previously reported about
CT sensitivity of extrinsically activated TEM tests [40].
It is questionable if this phenomenon has any clinical
relevance. The currently scientific rationale rather sug-
gests that PCCs might be associated to overshot throm-
bin generation with the potential to induce disseminated
intravascular coagulation and that Antithrombin III sup-
plements might mitigate this potentially dangerous ad-
verse effect [41]. The complete absence of antithrombin
in the final CRF composition is a major limitation of our
experiments and the effects of PCC supplements in clin-
ical situations with reduced antithrombin levels will have
to be analyzed in future trials.
A further limitation of our experimental studies is the
complete absence of red blood cells. Red blood cells
seem to exert a more important role in primary
hemostasis, whereas their modulating effect on second-
ary hemostasis seems to be negligible [13]. The fact is
that, viscoelastic studies can be reliably performed in
plasma samples [12, 13]. Surprisingly, an inverse relation
between hematocrit and clot firmness was previously re-
ported under experimental and clinical anemic condi-
tions [42]. We cannot rule out that the presence of red
blood cells in our in vitro model could lead to a measur-
able reduction of clot firmness parameters. However, fol-
lowing reports of Schoergenhofer et al. [13] no effects
on other TEM parameters should be expected under
whole blood conditions. Under massive transfusion
using CRF as a plasma substitute, transfusion of red
blood cells would be an integral part of the clinical man-
agement to uphold an adequate amount of oxygen car-
riers within the circulating blood volume.
Altogether, the transfer of our data into a clinical con-
text must therefore be done very carefully. All factor
components of CRFs have previously been safely admin-
istered in loose compositions for the management of
bleeding associated coagulopathy [43]. PCCs show a reli-
able safety profile and are now the treatment of choice
for the emergency reversal of Vitamin K antagonists [44,
45]. Nevertheless, a careful assessment of the thrombo-
genic potential of fixed factor combinations for the treat-
ment of a multiple factor deficit under massive bleeding
will have to be performed in future studies.
Conclusions
Coagulation factor concentrates suspended in albumin
solutions have the potential to restore mechanisms of
secondary hemostasis in the absence of any blood com-
ponent, showing viscoelastic properties comparable to
whole blood when tested in presence of platelets. Coagu-
lation factor enriched albumin-based colloids could be a
valuable tool to provide stable intravascular volume ef-
fects in hypovolemic conditions and to simultaneously
maintain basic coagulation mechanisms. This could offer
future alternatives to transfusion of fresh frozen plasma
under resuscitation conditions.
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